An observational study in Neovascular Age-related Macular Degeneration, sponsored by Notal Vision Inc.. Status unknown at 7 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2022-03-09.
Sponsored by Notal Vision Inc. · Observational
This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. The study will enroll subjects diagnosed with NV-AMD in at least one eye with attention to the proportion of eyes with IRF and/or SRF. The enrolled eligible subjects will be instructed to self-image the study eye(s) once daily for 5 weeks using a NVHO device at home with scheduled in-office examinations at Week 1, Week 5 and Interim Visits, when applicable, with additional in-office Cirrus volume scans acquired at these office visits. The self-imaging data on the NVHO will be automatically uploaded to the Notal Health Cloud and from there the reconstructed volume scans will sent to the study database.
The objectives of this study are to (1) evaluate the agreement, via positive percent agreement (PPA) and negative percent agreement (NPA), between OCT images captured by the NVHO and by the Zeiss Cirrus HD-OCT in the visualization of fluid as identified by a RC, in the central 10 degrees of the macula of NV-AMD patients, and (2) evaluate the ability of subjects diagnosed with NV-AMD to set up the device and self-image their eyes at home with the NVHO device (rate of successful imaging attempts).Description of Study Visits and Procedures:
Enrollment Visit:
At this visit, the exams will be conducted in the following order:
The following data will be collected for each study subject:
One or both eye(s) of the subject that meets all screening criteria, including having a diagnosis of NV-AMD in at least one eye previously or at the enrolment visit, will be enrolled in the study.
NOTE: For the subjects with both eyes with NV-AMD, one eye will be randomly selected as the primary eye during enrollment and the other will be the secondary eye. For subjects with only one eye with NV-AMD, the fellow eye with dry AMD may be enrolled. For such subjects, the NV-AMD eye will be the primary eye and the other eye will be the secondary eye.
The following data will be collected for the study eye:
i. Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings
Home Set-up with Remote Assistance (NVHO Setup Period)
Following confirmation of subject eligibility at the Enrollment Visit and the subject is enrolled in the study:
The subject will follow the steps detailed in the Set-up Guide included in the box. This is considered NVHO Setup Period.
Note: A care giver, family member or friend is allowed to assist. At most four additional calibrations can be performed, on the same day or different consecutive days, for each study eye if the calibration is not successful.
Note: If an eye cannot calibrate during 5 separate attempts, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
In-Home Phase (Day 1 to Day 35 post NVHO Setup Period) Following set-up of the NVHO,
Days 2-35: The subject will perform one self-imaging session each day on the study eye(s) with the NVHO device followed by automated transmission. Each scan has a reliability score provided by the NVHO.
Note: If an eye fails to self-image five consecutive times, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
Week 1 (Post NVHO Setup Period)
Subjects will return to the clinic for an office visit one week after the NVHO Setup Period (Home Set-up). The sponsor will provide transportation upon request. At this visit, the exams will be conducted in the following order:
Subjects will return to the clinic for an office visit five weeks after the NVHO Setup Period (Home Set-up). At this visit, the exams will be conducted in the following order:
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
This study's planned enrollment of 120 is above the median of 106 across 421 observational studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Notal Vision Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult subjects diagnosed with neovascular age-related macular degeneration (NV-AMD) in at least one eye at the time of enrollment.
Adults diagnosed with NV-AMD in at least one eye based on the subject's medical record. Fellow eyes diagnosed with dry AMD may be included as secondary eyes to a primary eye diagnosed with NV-AMD.
Note: eyes whit other pathologies including pseudocysts, outer retinal tabulations, pigments epithelial, detachments, hemorrhage, sub retinal hyper reflective material (SHRM), geographic atrophy and sub RPE, hypo reflective areas can be enrolled.
Exclusion Criteria:
Positive percent agreement
Positive percent agreement (PPA) of fluid status when comparing the fluid status in the central 3mm X 3mm of the NVHO volume scan graded by an independent reading center to the fluid status in the central 3mm X 3mm of Cirrus volume scan graded by an independent reading center.
Time frame: 1 month following reading center grading completion
Negative percent agreement
Negative percent agreement (NPA) of fluid status when comparing the fluid status in the central 3mm X 3mm of the NVHO volume scan graded by an independent reading center to the fluid status in the central 3mm X 3mm Cirrus volume scan graded by an independent reading center.
Time frame: 1 month following reading center grading completion
Percentage of subjects who successfully completed the setup of the NVHO device
Percentage of subjects who successfully completed the setup of the NVHO, indicated by the initiation of the tutorial.
Time frame: 5-10 minutes
Percentage of subjects who Successful completed NVHO self-imaging
Percentage of subjects who Successful completed NVHO self-imaging, namely a volume macular scan has been captured.
Time frame: 2-3 minutes
Percentage of all sessions that were transmission successfully
Percentage of sessions transmitted successfully to the Notal Health Cloud to the Notal Health Cloud .
Time frame: 10-15 minutes
Percentage of sessions containing self-imaging that were transmitted successfully
Percentage of sessions containing self-imaging that were transmitted successfully to the Notal Health Cloud.
Time frame: 10-15 minutes
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Notal Vision Inc.